Cipla Limited has said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection 100mg /ml and 200mg /ml from the United States Food and Drug Administration (USFDA). Cipla’s Testosterone Cypionate Injection 100mg /ml and 200mg /ml is A O - rated generic therapeutic equivalent version of Pharmacia and Upjohn’s Depo - Testosterone ® . It is indicated for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.
According to IQVIA (IMS Health), Depo - Testosterone ® and its generic equivalents h ad US sales of approximately USD 191 M for the 12 - month period ending April 2018. Meanwhile, shares of the company were trading at Rs 605.90 apiece up 0.39 per cent from the previous close at 10:09 hrs on BSE.
Best services for customers with full technical support make your Financial Trading more easy click here to subscribe us for free >> Nifty Market Tips
No comments:
Post a Comment